Skip to content
← All articles
Product Regulations

Australia UDI Rules for Medical Device Suppliers and Distributors

Zilch Team · · Regulatory guide · Information reviewed

Australia's Unique Device Identification rules are already being phased in. The first mandatory stage started on 1 July 2026 for Class III and Class IIb medical devices, subject to the applicable exemptions and transitional arrangements.

For a medical device supplier, the practical work is to establish which devices are covered, who is the Australian sponsor and whether the identifiers, labels and database records agree.

A barcode on a box is not enough to answer those questions. A distributor's internal SKU, an ARTG inclusion and a Unique Device Identifier each have a different job.

This guide focuses on Australia. It explains the main decisions to make across your catalogue and the information to request from manufacturers and sponsors.

What a UDI identifies

A Unique Device Identifier has two main parts. The UDI-DI identifies the device model. The UDI-PI identifies production information such as a lot, batch, serial number or relevant date, according to the device and labelling requirements.

The distinction matters operationally. If a recall affects one batch, a model identifier alone cannot tell you which stock is affected.

The TGA's identifier guidance also explains that the UDI-PI is not stored in the Australian UDI Database, or AusUDID. The database holds device identification and related reference information. It does not replace your transaction-level batch or serial traceability records.

Keep your internal SKU, manufacturer model code, UDI-DI and relevant ARTG inclusion linked. Avoid forcing them into one field simply because they all look like product numbers.

Which devices are covered

UDI does not apply identically to everything sold into healthcare.

The TGA's scope guidance includes Class Is, IIa, IIb and III medical devices, with specified exemptions. Class I nonsterile nonmeasuring devices and Class Im devices are outside the mandatory scope.

For in vitro diagnostic devices, Classes 2, 3 and 4 are covered. Class 1 IVD coverage is limited to instruments and software. Other exceptions also apply, so a catalogue-wide assumption based only on the word "medical" will be wrong.

Begin with the classification and ARTG position of each device family. Where a classification or exemption is uncertain, have the sponsor or regulatory specialist resolve it before scheduling labelling changes.

The main rollout dates

The standard start dates for UDI labelling and record submission are:

Standard UDI start dates for labelling and AusUDID submission
Start dateDevices
1 July 2026Class III and Class IIb medical devices
1 July 2027Class IIa medical devices
1 July 2028Class Is medical devices and Class 3 and 4 IVDs
1 July 2029Class 2 IVDs and the Class 1 IVDs in scope
Direct marking of reusable devices follows separate, later milestones. Existing devices may qualify for transitional arrangements, so assess eligibility device by device.

These are the headline dates, not a substitute for checking your device's transition arrangements. Direct marking has separate milestones where it applies. The TGA provides a device-specific timing tool and detailed implementation guidance.

Establish whether you are the sponsor

"Distributor" describes a commercial activity. It does not settle your regulatory role.

You might buy finished devices from an Australian sponsor and resell them. You might also arrange imports and act as sponsor yourself. The obligations are different, and one company may hold more than one role.

The TGA assigns responsibilities to manufacturers and sponsors. Manufacturers allocate the relevant identifiers and apply compliant carriers. Sponsors confirm the manufacturer's compliance, agree the data-submission arrangements and maintain accurate AusUDID records.

Using a third party to submit data does not remove the sponsor's responsibility for it. Record who owns the task rather than assuming the overseas manufacturer, Australian agent or software provider is handling it.

For a distributor that is not the sponsor, the sensible operational role is to obtain the correct identifiers and supplier information, preserve product identity and escalate discrepancies to the responsible sponsor.

Build a catalogue register before changing labels

For each relevant model, collect the manufacturer, Australian sponsor, classification, ARTG inclusion, internal SKU and UDI-DI. Include packaging identifiers where applicable, the compliance date and the basis for any transition or exemption.

Also record who confirmed the information and when. An unverified number in a spreadsheet can spread through your ERP, customer catalogue and warehouse labels surprisingly quickly.

Use separate fields for missing information and out-of-scope items. A blank field cannot tell a reviewer whether the device is exempt or whether nobody has asked the manufacturer yet.

The register should identify the next action for every gap. That might be confirming the sponsor, requesting a label image or correcting a mismatch between model descriptions.

Check packaging levels and scanning

A device's base pack, higher packaging levels and logistics units are not interchangeable. The TGA's labelling guidance explains the relevant packaging requirements and exceptions.

For your operations, test what is physically received and sold. A unit, box and carton may each have a different identifier and quantity relationship.

Scan representative labels into the systems your team uses. Confirm that identifiers retain leading zeros and that production information is interpreted correctly. Check whether a scan identifies the saleable pack or the individual device.

A spreadsheet that displays the right number is useful. A warehouse process that reliably captures the right item and batch is the part that makes the information operational.

Understand the AusUDID submission task

The sponsor needs a process for submitting and maintaining the applicable UDI records, including their links to ARTG inclusions. Establish which submission method you will use and who checks validation results.

The TGA's June 2026 timing guidance explains submission within 30 days of relevant supply under the standard milestone, with examples and special arrangements. Work through the example that matches your device and transition status rather than applying a single deadline to every item.

In practice, keep evidence that the submission was accepted and that the published record matches the device. A prepared upload file and a successful record are different stages of the job.

Also establish how corrections and product changes reach the responsible person. UDI compliance continues after the first upload.

Handle existing stock and product changes deliberately

Existing devices can have transitional treatment based on their classification, manufacturing and labelling dates, sponsor control and other eligibility conditions. European regulatory transitions may also affect the analysis.

Do not assume every older device must be relabelled immediately. Equally, "we already had it in the warehouse" is not sufficient to establish that a transition applies.

Keep the supporting facts with the stock decision and consult the TGA's detailed timing guidance. Track batches separately if different stock has different treatment.

For new products and changes, include UDI in the change-control process. A manufacturer may introduce a change that requires a new UDI-DI. Your customer catalogue and internal mapping must then be updated without losing the history of earlier devices.

Avoid the common data mistakes

An ARTG inclusion can cover multiple device models. It therefore does not replace the identifier required for each model.

An overseas UDI also needs to be assessed against Australian requirements. The existence of a US or European record does not, by itself, complete the sponsor's AusUDID obligations.

Finally, UDI does not establish that a device is suitable for every clinical use or that all other regulatory requirements have been met. It supports identification within the wider medical-device framework.

These distinctions should be reflected in staff training. Sales, purchasing and warehouse teams do not all need to become regulatory specialists, but they should know which number they are handling and where to escalate a mismatch.

Turn readiness into an operating process

Choose a representative device family and follow it from manufacturer information to incoming goods, customer data and the relevant AusUDID record. Resolve the gaps before expanding the process across the catalogue.

Zilch can be discussed as part of the broader work of organising product evidence and supplier evidence. This guide does not imply that Zilch issues UDIs, performs regulatory assessments or submits records to AusUDID. Confirm any specialist UDI software or integration requirement separately.

Talk to Zilch if collecting supplier information and keeping catalogue evidence organised is the bottleneck. Bring your device-data requirements so the scope can be assessed against the work you actually need done.

Sources and further reading